New Horizons in the Treatment and Management of B-Cell Non-Hodgkin Lymphoma: A Closer Look at the Role of Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca LP and Merck Sharp & Dohme Corp.

Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. B-cell lymphomas make up most (about 85%) of the NHL in the United States, with diffuse large B-cell lymphoma (DLBCL) being the most common at one in three b-cell lymphomas. Recent advances in disease management and our understanding of the biology of NHL have led to a dramatic change in the treatment landscape. Despite this progress, most b-cell NHL has a poor prognosis. Fortunately for patients with NHL, several new agents have become available, including targeted therapy options. They have shown the ability to improve safety and efficacy outcomes, especially in patients with relapsed disease that have had other therapies. However, with each new treatment, medical directors, oncologists, nurses and other healthcare professionals must stay abreast of the underlying mechanisms, current data, and treatment-emergent adverse events to provide their patients with optimal care. The amount of information surrounding emerging treatments for NHL can be daunting; this conference session will provide these healthcare professionals with a much-needed, concise overview of the available data and treatment paradigm.

There are various treatment options for NHL based on the severity of associated symptoms and the rate of cancer growth. Active treatment is started if the patient begins to develop lymphoma-related symptoms or there are signs that the disease is progressing based on testing during follow-up visits. After treatment, many patients can go into a remission that lasts for years; however, this disease should be considered a lifelong condition. Thus relapsed (returns after treatment) disease can occur. Fortunately, clinicians have been equipped with new targeted options for many of the b-cell NHLs, including bruton tyrosine kinase (BTK) inhibitors, in the past few years for patient's whose disease has relapsed, which provide options for the unmet need of treatment in b-cell NHL. Additionally, the BTK inhibitors that have been approved have indications are growing to include more and more types of b-cell NHL. These options have shown improved efficacy and safety in b-cell NHL, and healthcare professionals must be educated on these options, how they should be integrated into the treatment paradigm, and the potential risks that come along with any treatment option.

Upon completion of this activity, participants will be able to:

  • Analyze the efficacy and safety of novel targeted and immunotherapy agents in the management of B-cell non-Hodgkin lymphomas (NHL)

  • Examine the role of second generation BTK inhibitors in the management of B-cell NHL, with a close look at previously treated B-cell NHL

  • Distinguish among available and emerging BTK inhibitors and PI3K inhibitors with respect to their isoform specificity, associated adverse effect profiles, dosing and administration, and clinical efficacy, safety, and tolerability in the management of B-cell NHL

  • Define the risks and adverse events associated with novel therapies indicated for the treatment of patients with B-cell NHL in order to maximize tolerability and adherence to therapeutic regimens

  • Assess the managed care considerations of current and emerging therapies by exploring where these agents fit into the current B-cell NHL management paradigm

Faculty: Owen A. O'Connor, MD, PhD
American Cancer Society Research Professor
Professor of Medicine and Experimental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center


Dr. O'Connor serves on an advisory board for Millennium, Mundipharma, Seattle Genetics, and TG Therapeutics. He has received grant/research support from Affimed, Agensys, Celgene, Merck, Seattle Genetics, Spectrum, TG Therapeutics, and Trillium. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca LP and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue